

ONE HUNDRED FIFTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-2927  
Minority (202) 225-3641

June 26, 2018

Dr. M. Michelle Berrey  
President and CEO  
Chimerix, Inc.  
2505 Meridian Parkway; Suite 100  
Durham, NC 27713


Dear Dr. Berrey:

Thank you for appearing before the Subcommittee on Health on June 6, 2018, to testify at the hearing entitled "Reauthorizing the Pandemic and All-Hazards Preparedness Act."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on July 11, 2018. Your responses should be mailed to Daniel Butler, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to [daniel.butler@mail.house.gov](mailto:daniel.butler@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Michael C. Burgess, M.D.  
Chairman  
Subcommittee on Health

cc: The Honorable Gene Green, Ranking Member, Subcommittee on Health

Attachment

## Attachment—Additional Questions for the Record

### The Honorable Markwayne Mullin

1. Do you all believe that current law puts some constraints on how BARDA is able to partner new companies and new technologies?
  - a. Follow up: Can you explain to me the limits of BARDA's authority to work with companies developing non-therapeutic technologies to counter antibiotic and antimicrobial resistance?
  - b. Follow up: Do you believe giving BARDA the flexibility to work with companies more broadly would be beneficial to BARDA as they work to achieve their mission to counter anti-biotic and antimicrobial resistance?

### The Honorable Earl L. 'Buddy' Carter

1. In your written testimony you discussed how the passage of the Project BioShield Act, then PAHPA, created a market for medical countermeasures for the first time that created incentives for companies to develop countermeasures. In your view, do you believe this legislation will help industry research and develop the therapies necessary to combat the biomedical threats facing this nation? In your past experiences, what have been some of the challenges your company has faced working to develop countermeasures?

### The Honorable Frank Pallone, Jr.

1. What assistance has Chimerix received from the federal government in the development of your product, brincidofovir?
2. How much of the research and development costs related to brincidofovir have been secured from private sources?
3. Do you believe that providing stable, advance appropriations for medical countermeasure development and procurement would be a sufficient incentive to encourage other manufacturers to enter the biodefense space?